This recombinant monoclonal antibody is a research-grade biosimilar to ABBV-927, designed for research targeting CD40, a member of the tumor necrosis factor receptor superfamily. CD40 is a costimulatory protein expressed on antigen-presenting cells, B cells, and various non-immune cells, playing a crucial role in adaptive immunity through its interaction with CD40 ligand (CD40L). This interaction regulates B cell activation, immunoglobulin class switching, and the generation of memory B cells. CD40 signaling is implicated in autoimmune diseases, inflammatory conditions, and cancer, where it influences both tumor immunity and tumor cell survival depending on the cellular context.
ABBV-927 is an investigational agonistic antibody that has been evaluated in clinical studies for its potential to enhance anti-tumor immune responses in cancer therapy. This biosimilar provides researchers with a valuable tool for investigating CD40-mediated immune mechanisms, studying tumor immunology, evaluating therapeutic strategies in oncology models, and exploring the role of costimulatory pathways in immune regulation and disease pathogenesis.
Email: support@cusabio.com
Distributors Worldwide